Benzinga | May 26, 2021 04:18PM EDT

Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids

* In the Phase 3 LIBERTY 1 and LIBERTY 2 studies, MYFEMBREE demonstrated 72.1% and 71.2% response rates in menstrual blood loss (MBL) at Week 24, with MBL reductions of 82.0% and 84.3% from baseline

* Myovant and Pfizer will jointly commercialize MYFEMBREE, with product availability expected in June

* Myovant to host conference call and webcast on Friday, May 28, 2021 at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time